Applying the biopharmaceutics classification system to veterinary pharmaceutical products Part II. Physiological considerations

被引:68
作者
Martinez, M [1 ]
Amidon, G
Clarke, L
Jones, WW
Mitra, A
Riviere, J
机构
[1] US FDA, Off New Anim Drug Evaluat, Rockville, MD 20855 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Missouri, Kansas City, MO 64110 USA
[4] Univ Missouri, Columbia, MO 65212 USA
[5] N Carolina State Univ, Raleigh, NC 27606 USA
关键词
biopharmaceutics classification system; interspecies differences; veterinary oral drug absorption; animal models; food effects; lymphatic uptake;
D O I
10.1016/S0169-409X(02)00071-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
in comparing product bioavailability across animal species, it is not unusual to observe marked interspecies differences. For many compounds, these differences reflect presystemic drug metabolism. However, a host of other variables must also be considered such as in vivo drug solubility, gastric transit time, intestinal permeability, diet, and species-by-formulation interactions. By combining information on drug solubility and intestinal permeability with an understanding of the interrelationship between pH, product dissolution and gastrointestinal physiology, we attempt to define those conditions under which in vitro dissolution data may be used as a surrogate for data on in vivo bioavailability. We consider the likely physiological causes for species-related differences in the absolute and relative bioavailability of orally administered pharmaceuticals, and examine the potential for these normal interspecies differences to reflect bioavailability changes that can occur with various human pathologies. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:825 / 850
页数:26
相关论文
共 160 条
[61]   NORMAL COLONIC BACTERIAL-FLORA [J].
HILL, MJ ;
DRASAR, BS .
GUT, 1975, 16 (04) :318-323
[62]   ACETAMINOPHEN ABSORPTION AND METABOLISM IN CELIAC-DISEASE AND CROHNS-DISEASE [J].
HOLT, S ;
HEADING, RC ;
CLEMENTS, JA ;
TOTHILL, P ;
PRESCOTT, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :232-238
[63]  
Hoogdalem E.J., 1997, J PHARM SCI, V86, P1156
[64]   GASTROINTESTINAL TRANSIT OF NONDISINTEGRATING, NONERODIBLE ORAL DOSAGE FORMS IN PIGS [J].
HOSSAIN, M ;
ABRAMOWITZ, W ;
WATROUS, BJ ;
SZPUNAR, GJ ;
AYRES, JW .
PHARMACEUTICAL RESEARCH, 1990, 7 (11) :1163-1166
[65]  
HUI YF, 1994, BIOCHEM PHARMACOL, V48, P229
[66]  
IBRAHIM SA, 1995, INDIAN J BIOCHEM BIO, V32, P290
[67]   EFFECT OF OILY VEHICLES ON ABSORPTION OF MEPITIOSTANE BY THE LYMPHATIC-SYSTEM IN RATS [J].
ICHIHASHI, T ;
KINOSHITA, H ;
TAKAGISHI, Y ;
YAMADA, H .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (07) :560-564
[68]   METABOLISM OF DRUGS AND OTHER XENOBIOTICS IN THE GUT LUMEN AND WALL [J].
ILETT, KF ;
TEE, LBG ;
REEVES, PT ;
MINCHIN, RF .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (01) :67-93
[69]   Evaluation of colonic absorbability of drugs in dogs using a novel colon-targeted delivery capsule (CTDC) [J].
Ishibashi, T ;
Ikegami, K ;
Kubo, H ;
Kobayashi, M ;
Mizobe, M ;
Yoshino, H .
JOURNAL OF CONTROLLED RELEASE, 1999, 59 (03) :361-376
[70]  
JACKSON MJ, 1987, PHYSL GASTROINTESTIN